Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival
Pooled Analysis of 12 Seperate Yervoy Studies Shows Survival-Curve Plateau at 3 Years
Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer
ASCO and CAP Issue Guideline To Improve HER2 Testing
Phase III Ramucirumab Trial Fails Primary Endpoint of PFS
Kadcyla Extends Median PFS In Open-Label Phase III Trial
Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease
Colon Polyps in Elderly Patients Are More Likely to Be Found Only with Colonoscopy
Phase III Vaccine Trial Fails To Improve Overall Survival
Central Line Safety Intervention Lowers Patient Infection Rate
Phase II Study Shows Positive Results in Reducing Dry Mouth
NCI CTEP Approved Trials For the Month of October
Trending Stories
- Narjust Duma named associate director of the Cancer Care Equity Program at DFCI, Harvard Medical School
- Robert Stone: City of Hope aims to transform cancer care nationally through new models, partnerships
- Biden commits to creating “ARPA-H” research body in visit to Ohio State
- Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- The Cancer Letter gets a new website
You may have noticed that things are looking different around here - Abecma receives FDA approval for multiple myeloma
